Objectives To develop population pharmacokinetic (PK) models for piperacillin/tazobactam
in neonates and infants of less than 2 months of age in order to determine the appropriate …

Objectives: To characterize the population pharmacokinetics of piperacillin and tazobactam
in critically ill infants and children, in order to develop an evidence-based dosing regimen …

Piperacillin-tazobactam (TZP) is frequently used to treat severe hospital-acquired infections
in children. We performed a single-center, pharmacokinetic (PK) trial of TZP in children …

Piperacillin/tazobactam, an intravenous antibacterial combination product, has recently
been approved for paediatric (age 2 months to 17 years) use in the USA. The purpose of this …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of extended-infusion piperacillin-tazobactam in children hospitalized in …

Piperacillin-tazobactam is often given to infants with severe infection in spite of limited
pharmacokinetics (PK) data. We evaluated piperacillin-tazobactam PK in premature and …

The pharmacokinetics of piperacillin and tazobactam were assessed after single-dose
administration to 47 infants and children. Study subjects ranging in age from 2 months to 12 …

Methods: Blood samples (2–4 per child) were collected from 13 children ages 9 months to 6
years admitted to the pediatric intensive care unit who were receiving standard piperacillin …

Background: Piperacillin, in combination with tazobactam, is frequently used in infants for
treating nosocomial infections, although safety data in this population are limited. Electronic …

An open, non-comparative study was designed to evaluate the safety and toler-ance of
parenteral piperacillin/tazobactam in very low birth weight infants. Twenty-seven patients …